Kelvin G M Brockbank
Tissue Testing Technologies LLC, USA
Keynote: J Tissue Sci Eng
End-stage organ disease accounts for over 700,000 US deaths annually. Ice-free vitrification is an alternative cryopreservation strategy to conventional freezing that holds great promise as a means of banking tissues and organs. Vitrification is the amorphous solidification of a supercooled liquid, achievable by adjusting the cryoprotectant concentration and cooling rate to minimize ice crystal nucleation and growth, in a glassy state. Without ice crystal formation, the biospecimens├ó┬?┬? extracellular matrix and cell viability is better preserved. The decision to utilize an ice-free versus a freezing method for different types of biospecimens depends on which method is easiest for the product. Generally, cells and tissues can be preserved using ice-free vitrification but isolated cells are usually easier to preserve using freezing methods. Ice-free vitrification has major advantages for preservation of tissues such as ovaries, heart valves, articular cartilage, blood vessels and more recently tissue engineered arteries, skin and cornea provided that the total volume of tissue and solution is no more than 5 mL. At larger volumes, it is difficult to vitrify without ice forming because cooling and warming rates become limiting factors, cryoprotectant toxicity also becomes an issue as the tissue sample size increases. These hurdles need to be overcome if the promise of dramatically improving organ and tissue banking is to become a reality alleviating the growing economic burden of organ impairment. Progress towards these objectives using supplements to control excessive ice formation, new cooling & warming techniques and analytical methods will be reviewed.
Kelvin G M Brockbank is the CEO and Founder of Tissue Testing Technologies LLC, and Research Professor of Bioengineering, Clemson University. His research interests include cell, tissue and organ cryopreservation for test systems and transplantation and manufacturing methods for cell-based tissue engineered therapy products. His work has established two successful public-traded low temperature technology platform companies, CryoLife, Inc., and Lifeline Scientific. He received the “George W Hyatt Memorial Award” for superior service in the fields of tissue banking and human transplantation in 2009 and is Vice Chairman of the Scientific and Technical Affairs Committee of the American Association of Tissue Banks.
Journal of Tissue Science and Engineering received 715 citations as per Google Scholar report